Regeneron plots new course with Vagelos

The message from Regeneron Pharmaceuticals Inc.'s appointment of Roy Vagelos as chairman is that the company plans to remain independent.

REGN's board has been looking at strategic alternatives for the Tarrytown, N.Y., company since the failure last March of its Phase III trial of ciliary neurotrophic factor (CNTF) in amyotrophic lateral sclerosis...